ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Project Expands Group Studies To Community Oncologists.

March 10, 2000

Harkin, Specter Propose A $5.2-Billion Supplement For NIH. Senate Report Says NIH Funding At “Crisis Point.”

July 18, 2008

Why Shouldn’t Scientific Issues Be Discussed In Open Meetings? Editorial

November 10, 1989

In Brief: Landers Needles Pauling on Vitamin C Study Results; David Goldenberg Heads N.J. Center

October 21, 1983

NCI Programs: Report Calls for Expansion of Colorectal Cancer Research

April 28, 2000

HHS To Announce Final Plan For Coverage Of Patient Care Costs In All Clinical Trials.

July 28, 2000